
“With constant changes to both the clinical aspects and policy impacting the practice of oncology, clinicians are calling for business professionals to be well-versed in relevant information beyond the products they represent,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “As an authoritative source in oncology care, NCCN is pleased to offer robust, educational programs through NCCN Academy that can help professionals integrate key advances and marketplace changes into their business operations and decisions.”
NCCN Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business provides pharmaceutical and biotechnology professionals with the significant opportunity to view the oncology space, its future and its current operational issues from the provider and payer perspective. Participants will improve their working knowledge of key business, policy, coverage, reimbursement, informational, and operational issues in oncology and will gather valuable insights into developing effective strategies for navigating the various constituencies in cancer care. Through this interactive program, pharmaceutical and biotech professionals will learn from key stakeholders what they view to be the most pressing issues in oncology today and how to apply this knowledge to create mutually-successful working relationships. Further, they will hear thought leaders discuss how their decisions and programs are shaped by certain types of information and data.
Professionals from marketing, sales, medical affairs, clinical research, policy and government affairs, and other business areas will all be better able to serve their customers with improved knowledge of real-world oncology issues following the completion of this program.
Faculty may comprise representatives from the academic and community provider settings, as well as payor, government, Wall Street, pharmaceutical and biotech constituents, among others.
NCCN appreciates all of our prestigious speakers who generously dedicate their time and insights to making each NCCN Academy program an unmatched experience for our audiences. To review the faculty roster for future programs, please refer to Upcoming Academy Programs.
“These programs are important and will build the bridges we so desperately need at this time. I am glad to be part of your program and to play my part in its success.”
- Michael K. Wong, MD, PhD, Medical Director for Clinical Drug Development and Biologic Therapy for Melanoma, Sarcoma and Genitourinary Cancers, at Roswell Park Cancer Institute in Buffalo, New York.
Below are a few of the comments we’ve received:

Privacy Policy| Legal Notices| Site Map| Contact Us| Help
Copyright © 2010 National Comprehensive Cancer Network, All Rights Reserved